Medtronic Plans Trial for Drug Therapy with Stent

Medtronic says it will conduct a randomized clinical to evaluate one-month dual antiplatelet therapy (DAPT) — the combination of aspirin and an anti-clotting medication — in patients implanted with the Resolute Onyx Drug-Eluting Stent (DES) during percutaneous coronary intervention. The study is intended to help provide DAPT guidelines for newer-generation DES that currently favor bare-metal stents for patients with stable ischemic heart disease who might require a shorter dual antiplatelet regimen.

The Resolute Onyx DES is the first stent to feature Core Wire Technology, Medtronic’s method of stent manufacturing that involves forming a single strand of cobalt alloy wire into a sinusoidal wave to construct a stent. “This enables greater deliverability and conformability to the vessel wall,” the company says. “Core Wire Technology also enables thinner struts while maintaining structural strength.”